SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

$SLV is trending as silver nears multi-decade highs, sparking community discussion around a potential short squeeze and anticipation of further gains. Some community members are discussing theories around market manipulation and speculating about triple-digit prices, while others highlight the potential for a significant breakout after years of price suppression. Investors are closely watching silver's momentum amid concerns about inflation and the dollar's stability.

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

TMC is trending as the community rallies behind the stock, citing potential short squeezes and government support amid increasing demand for critical minerals. The stock's price movement and sector momentum are fueling discussions, with many anticipating a continued climb. Bullish investors express strong conviction in TMC's long-term prospects.

Aventus Network

Aventus Network ($AVT) is trending, with community members discussing its potential and recent partnerships. Some are pointing to its low market cap and real-world applications in cargo management as reasons for optimism. Mentions of its integration with Polkadot and listing on Coinbase are also circulating.

Global Health Solutions Inc is an American company that works with partners to eliminate diseases that have plagued humanity for centuries and protect the health of populations by helping countries build strong health systems. The private company is located in the US. The company brings together key stakeholders around the world with a common goal to stop diseases and strengthen health systems through powerful partnerships. The company consists of programs and focus areas that cover a range of health issues including neglected tropical diseases, infectious diseases, vaccines, field epidemiology, public health informatics, health workforce development, and health ethics. The company's end goal is to eliminate diseases and protect the health of populations.

Turn Therapeutics Inc.

Turn Therapeutics Inc

Turn Therapeutics ($TTRX) is trending after its recent IPO, with the community discussing its potential for significant gains. Some traders are cautious, pointing to valuation concerns and possible formations on the minute chart, while others see it as the next stock poised for a substantial surge, drawing comparisons to other recent high-flying IPOs.

First Majestic Silver Corp. engages in the production, development, exploration and acquisition of mineral properties. It owns and operates producing mines in México including the La Encantada Silver Mine, La Parrilla Silver Mine, San Martin Silver Mine, La Guitarra Silver Mine, Del Toro Silver Mine, Santa Elena Silver & Gold Mine, and San Dimas Silver & Gold Mine. The company was founded by Keith Neumeyer on September 26, 1979 and is headquartered in Vancouver, Canada.

First Majestic Silver Corporation

First Majestic Silver is trending as spot silver prices reach new highs, sparking excitement among investors. The community is actively discussing loading up on silver miners and anticipating further gains, drawing comparisons to gold's previous rallies. Some are pointing out the potential for silver miners to go mainstream, while others are debating realistic price targets.

Serve Robotics, Inc. engages in providing self-driving delivery. It designs, develops, and operates zero-emissions robots that serve people in public spaces, starting with food delivery. The company was founded by Ali Kashani, Dmitry Demeshchuk and MJ Burk Chun in 2017 and is headquartered in Redwood City, CA.

Serve Robotics Inc

SERV is trending after announcing a strategic partnership with DoorDash, expanding its autonomous delivery robot service nationwide and outside of the Uber Eats ecosystem. Community members are discussing the potential for increased delivery volume and expansion into new markets, with some eyeing price targets. The stock is gaining traction as investors show interest in the autonomous last-mile delivery space.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. TeraWulf will generate domestically produced bitcoin powered by nuclear, hydro and solar energy. The company was founded by Paul Prager and Nazar Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf is trending amid discussions of a potential short squeeze, driven by high short interest and growing optimism around its transition to AI/HPC data centers; the community is closely watching key resistance levels and anticipating a breakout. Positive sentiment is further fueled by Google's backing and potential approval of the Cayuga site, which could unlock significant capacity and revenue opportunities. Some traders are comparing it to the early stages of other AI plays.

Kratos Defense & Security Solutions, Inc. engages in the provision of mission critical products, services and solutions for United States national security priorities. It operates through the Kratos Government Solutions (KGS) and Unmanned Systems (US) segments. The KGS segment consists of an aggregation of KGS operating segments, including microwave electronic products, space, satellite and cyber, training solutions. The US segment refers to the unmanned aerial, unmanned ground, unmanned seaborne and related command, control and communications system businesses. The company was founded on December 19, 1994, and is headquartered in Round Rock, TX.

Kratos Defense & Security Solutions Inc

Kratos Defense & Security Solutions is trending as investors discuss its potential as a key player in the evolving defense sector, particularly regarding drone and hypersonic technology. Community members highlight the company's innovative solutions, potential for partnerships, and rising defense spending as catalysts, while also speculating on possible acquisition targets. Some investors believe KTOS is currently undervalued compared to other defense giants, while others express concern about an overvalued status.

Delta Air Lines, Inc. engages in the provision of scheduled air transportation for passengers and cargo. It operates through the Airline and Refinery segments. The Airline segment provides scheduled air transportation for passengers and cargo. The Refinery segment provides jet fuel to the airline segment. The company was founded by Collett Everman Woolman in 1928 and is headquartered in Atlanta, GA.

Delta Air Lines, Inc.

Delta Air Lines is trending after reporting strong Q3 earnings, exceeding expectations and raising full-year guidance, boosting investor confidence and lifting the entire airline sector. The community is actively discussing whether to hold or sell, anticipating further gains and a potential rise to new highs. Corporate sales and premium revenue growth reflect strong demand, and the CEO expresses optimism for continued momentum.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

VKTX is trending as investors speculate about a potential acquisition following increased M&A activity in the metabolic disease space, highlighted by the recent AKRO and MTSR deals. Community discussions revolve around potential buyout offers and the possibility of a short squeeze, with many believing VKTX is undervalued given its pipeline and recent data. The focus is now shifting towards MASH opportunities, adding another layer of potential value for the company.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Can BMYs Neuroscience Portfolio Help to Diversify Its Business? 

Bristol Myers gains FDA Fast Track status for its Alzheimer's antibody BMS-986446 as Cobenfy drives early sales and pipeline momentum.

Why Bristol Myers Squibb (BMY) is a Top Value Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Here's What to Expect From Pfizer's Oncology Drugs in Q3 Earnings

Pfizer's oncology strength, powered by Seagen's ADCs and key drugs like Xtandi and Lorbrena, is likely to be in focus ahead of Q3 earnings.

Bristol Myers Squibb (BMY) Registers a Bigger Fall Than the Market: Important Facts to Note

In the closing of the recent trading day, Bristol Myers Squibb (BMY) stood at $44.66, denoting a -1.06% move from the preceding trading day.

Can Novo Nordisk's Restructuring Program Drive its Return to Growth?

NVO is cutting 9,000 jobs, targeting DKK 8 billion in savings, and shifting focus to obesity and diabetes R&D to regain growth momentum.

Can CYTK Clinch a Potential FDA Nod for Its Cardiovascular Drug?

Cytokinetics' aficamten shows superiority over metoprolol in late-stage oHCM trial, boosting investor confidence despite FDA delay.

Bristol Myers Squibb (BMY) Beats Stock Market Upswing: What Investors Need to Know

Bristol Myers Squibb (BMY) reached $45.1 at the closing of the latest trading day, reflecting a +2.15% change compared to its last close.

Krystal Biotech's Heavy Reliance on Vyjuvek: Growth Driver or Risk Factor?

KRYS gains momentum with Vyjuvek's expanded FDA label and global approvals, while advancing a pipeline led by oncology candidate KB707.

The Pharmaceutical Research and Manufacturers of America (PhRMA), a lobbying organization, announced a new website on Monday that will connect patients with manufacturer-direct purchase programs.The website, AmericasMedicine.com, is scheduled to launch in January 2026, PhRMA <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://phrma.org/resources/phrma-announces-major-actions-as-part-of-industry-s-commitment-to-american-patients-and-workers">announced</a>. It will allow manufacturers to list a range of medicines and connect patients directly to available options prescribed by their doctor, it added. &nbsp;Pharmacy benefit managers (PBMs) and middlemen receive massive rebates on medicines while charging patients the full price, the organization noted. Direct purchase programs thus enable patients and employers to purchase medicines at a lower cost.The group represents several biopharmaceutical research companies, including Amgen (AMGN), Bristol Myers Squibb (BMY), and Merck (MRK). However, pharmaceutical manufacturers will make their own decisions to offer direct purchase programs, and if they want to participate in the new website, the group said.The announcement from the group coincides with the deadline set by President Trump for 17 pharmaceutical companies, including Amgen, Boehringer Ingelheim, Bristol Myers Squibb, EMD Serono, Roche unit Genentech, Gilead, GSK, Johnson &amp; Johnson, Novartis, Novo Nordisk, Regeneron, and Sanofi, to reduce drug prices in the U.S. to the levels paid by other wealthy countries.The group stated on Monday that it will continue to work with the Trump administration and Congress to address the real reasons U.S. medicine prices are higher.“To reduce price differentials with other wealthy countries, policymakers should require PBMs to share savings with patients, fix the 340B hospital markup program and force foreign governments to pay their fair share,” the lobby group said. It also noted that its member companies are making significant investments in U.S.-based manufacturing and infrastructure.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/datavault-ai-stock-jumpes-13-percent-after-announcing-partnetship-with-ibm/chDu22ZR3J9">Datavault AI Stock Jumps 13% After Announcing Partnership With IBM</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A photo illustration showing a mix of various tablets and pharmaceutical products, primarily manufactured by U.S. pharmaceutical companies, photographed in Edmonton, Alberta, Canada, on April 10, 2025 (Photo by Artur Widak/NurPhoto via Getty Images)

Pharma Lobby Announces New Website To Connect Patients With Manufacturer-Direct Purchase Programs

The announcement from the group coincides with the deadline set by President Trump for 17 pharmaceutical companies to reduce drug prices in the U.S. to the levels paid by other developed countries.

Equity

The announcement from the group coincides with the deadline set by President Trump for 17 pharmaceutical companies to reduce drug prices in the U.S. to the levels paid by other developed countries.


Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It

Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Bristol-Myers Squibb Co.

Will JP Morgan Chase ($JPM) beat quarterly earnings?  
 
*Powered by Polymarket

Stocktwits

JPMorgan Chase & Co

) beat quarterly earnings?  
 
*Powered by Polymarket

BMY
Bristol-Myers Squibb Co.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest BMY News

BMY Bristol-Myers Squibb Co.